Ablynx says top drug shows benefit over rival
BRUSSELS (Reuters) – Belgian drug developer Ablynx said on Monday its top drug, arthritis treatment ozoralizumab, had shown a benefit over its biggest rival in the $24 billion market for this class of treatment. The company, which makes ultra-small antibodies derived from llamas, said data showed few patients developed immunity to the drug, a problem which can affect its biggest rival Humira, produced by U. S. based Abbott Laboratories. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply